Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1
Published January 10, 2024 · Recall initiated: December 8, 2023
Summary
FDA records drug Class III recall D-0213-2024, published January 10, 2024 and initiated December 8, 2023. Recalling firm: Azurity Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 2,220 bottles; Lot: Lot #: MB22020B, Exp 12/27/2023. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.
What to do
Voluntary: Firm initiated · Letter
Get an email if EPRONTIA has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- EPRONTIA
- Manufacturer
- Azurity Pharmaceuticals, Inc.
- Distributor
- USA nationwide.
- Lot
- Lot #: MB22020B, Exp 12/27/2023
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANasal Spray Original No Drip Oxymetazoline HCl Nasal Solution, 12 Hour Pump Mist, 1 FL oz. (30 mL) bottle, a)January 10, 2024
- FDAPremier Value Tussin Cough DM, Dextromethorphan HBr...Cough Suppressant, Guaifenesin...Expectorant, AlcoholJanuary 10, 2024
- FDAQuality Choice No Drip Extra Moisturizing Nasal Pump Mist Oxymetazoline hydrochloride 0.05%, 12 Hour NasalJanuary 10, 2024
- FDADeRoyal CARDIAC CATH SET-UP KIT PGYBK, REF 89-10572January 3, 2024
- FDAAtrium Oasis Drain Single W / AC, Part No. 3600-100January 3, 2024
- FDALiberty Select Cycler, Model numbers RTLR180343 and RTLR180111January 3, 2024
Questions about this recall
Was Eprontia (topiramate) oral solution, 25 mg/mL, 473 mL Bottle, Rx only, Manufactured for: Azurity Pharmaceuticals, Woburn, MA 01801, NDC 52652-9001-1 recalled?
Yes. FDA published recall D-0213-2024 on January 10, 2024. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: EPRONTIA.